CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.

doi:10.1097/FTD.0000000000000119

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CYP1A21D and 1F polymorphisms have a significant impact on olanzapine serum concentrations.

Therapeutic drug monitoring - 1 Apr 2015

Czerwensky Fabian, Leucht Stefan, Steimer Werner

Abstract excerpt

BACKGROUND: Although several polymorphisms in olanzapine-metabolizing enzymes have been identified, the clear role and benefit for pharmacotherapy remain uncertain. The aim of the study was to investigate the potential influence of polymorphisms in the CYP1A2 gene (*1D,*1F), in the UGT1A4 gene (*3), and in the POR gene (rs2302429) on olanzapine serum concentrations and the clinical outcome. METHODS: Ninety-eight...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodiazepines

Share to Clozapine

Share to Cytochrome P-450 CYP1A2

Share to Cytochrome P-450 Enzyme System

Share to Glucuronosyltransferase

Share to Olanzapine

Share to Schizophrenia

Source

Open in PubMed

Identifiers

PMID: 25090458
DOI: 10.1097/FTD.0000000000000119

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.PMID 25090458Read ↗

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.Semantic proximity Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.Semantic proximity Read ↗

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.Semantic proximity Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.Semantic proximity Read ↗

Effect of Genetic Variants, Gender, and Co-treatment on Olanzapine Plasma Concentration in Chinese patients with schizophreniaSemantic proximity Read ↗

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Semantic proximity Read ↗

Interindividual Variability in Olanzapine Steady-State Concentrations in Chinese: Exploring Single Nucleotide Polymorphisms of Metabolic EnzymesSemantic proximity Read ↗

The Potential Role of POR*28 and CYP1A2*F Genetic Variations and Lifestyle Factors on Clozapine and N-DesmethylClozapine Plasma Levels in Schizophrenia Patients.Semantic proximity Read ↗

Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients.Semantic proximity Read ↗

Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in healthy volunteers. Association with pharmacogeneticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.